# US 2021/0277021 A1 · Tetrahydroisoquinoline derivative, preparation method therefor and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277021 A1
- Document ID: US20210277021A1
- Status: Published application
- Kind: A1
- Application number: 17/254,273
- Filed: 2019-06-18
- Published: 2021-09-09
- Earliest claimed: 2018-06-19
- Assignees: Zhejiang Hisun Pharmaceutical Co., Ltd.
- Applicants: Zhejiang Hisun Pharmaceutical Co., Ltd.
- Inventors: Yanghui GUO; Xiangui HUANG; Weiwei LIAO; Lichen MENG; Taishan HU; Lei CHEN; Guoping JIANG
- Web page: https://patentgrep.com/patent/US20210277021A1

## CPC

- C07D 498/04: Ortho-condensed systems
- A61K 31/423: condensed with carbocyclic rings
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are a tetrahydroisoquinoline derivative, a preparation method therefor and an application thereof in medicine. In particular, provided are a tetrahydroisoquinoline derivative represented by general formula (I), a preparation method therefor and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as an angiotensin II type 2 receptor (AT2R) antagonist, wherein definitions of substituent groups in the general formula (I) are the same as definitions in the description.

## Claims

### Claim 1

A compound represented by general formula (I) or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof:
wherein
R1, R4, R5 and R6 are each independently selected from hydrogen, hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more substituents selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —C(O)R9, —C(O)OR9, —OC(O)R9, —NR10R11, —C(O)NR10R11, —S(O)nNR10R11 and —NR10C(O)R11; preferably, R1, R4, R5 and R6 are each independently selected from hydrogen, alkyl, halogen and cyano;
R2 is selected from —ORa and —NRbS(O)nRc;
Ra is selected from hydrogen and alkyl;
Rb is selected from hydrogen and alkyl;
Rc is selected from hydrogen, alkyl, cycloalkyl and —NRdRe;
Rd is selected from hydrogen and alkyl;
Re is selected from alkyl, wherein the alkyl is optionally further substituted by one or more substituents selected from hydroxyl, halogen, nitro, cyano, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —C(O)R9, —C(O)OR9, —OC(O)R9, —NR10R11, —C(O)NR10R11, —S(O)nNR10R11 and —NR10C(O)R11;
or Rd and Re together with the N to which they are attached form a 4 to 8-membered heterocyclyl, wherein the 4 to 8-membered heterocyclyl contains one or more N, O or S(O)n, and the 4 to 8-membered heterocyclyl is optionally further substituted by one or more substituents selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, ═O, —C(O)R12, —C(O)OR12, —OC(O)R12, —NR13R14, —C(O)NR13R14, —S(O)nNR13R14 and —NR13C(O)R14;
R3 is selected from heteroaryl, wherein the heteroaryl is optionally further substituted by one or more substituents selected from Rf; preferably, R3 is selected from a 5-6 membered heteroaryl and a 8-10 membered heteroaryl;
Rf is selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —C(O)R9, —C(O)OR9, —OC(O)R9, —NR10R11, —C(O)NR10R11, —S(O)nNR10R11 and —NR10C(O)R11, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more substituents selected from hydroxyl, halogen, nitro, cyano, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —C(O)R9, —C(O)OR9, —OC(O)R9, —NR10R11, —C(O)NR10R11, —S(O)nNR10R11 and —NR10C(O)R11;
R7 is selected from hydrogen, halogen, alkyl, cycloalkyl, cyano and —ORs, wherein the alkyl or cycloalkyl is optionally further substituted by one or more substituents selected from hydroxyl, halogen, nitro and cyano;
Rg is selected from alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more substituents selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —C(O)R9, —C(O)OR9, —OC(O)R9, —NR10R11, —C(O)NR10R11, —S(O)nNR10R11 and —NR10C(O)R11; preferably, Rg is methyl;
R8 is alkyl, wherein the alkyl is further substituted by aryl or heteroaryl, wherein the aryl or heteroaryl is optionally further substituted by one or more substituents selected from Rh; the aryl is preferably C6-C10 aryl; the heteroaryl is preferably 5 to 6-membered heteroaryl;
Rh is selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —C(O)R9, —C(O)OR9, —OC(O)R9, —NR10R11, —C(O)NR10R11, —S(O)nNR10R11 and —NR10C(O)R11; wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more substituents selected from hydroxyl, halogen, nitro, cyano, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —C(O)R9, —C(O)OR9, —OC(O)R9, —NR10R11, —C(O)NR10R11, —S(O)nNR10R11 and —NR10C(O)R11;
preferably, R8 is selected from benzyl, pyridylmethylene, pyrimidylmethylene and pyridazinylmethylene, wherein the benzyl, pyridylmethylene, pyrimidylmethylene or pyridazinylmethylene is optionally further substituted by one or more substituents selected from fluorine, chlorine, cyano, methyl, trifluoromethyl, methoxy and trifluoromethoxy;
R9, R10 and R11 are each independently selected from hydrogen, hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more substituents selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —C(O)R12, —C(O)OR12, —OC(O)R12, —NR13R14, —C(O)NR13R14, —S(O)nNR13R14 and —NR13C(O)R14;
or R10 and R11 together with the N to which they are attached form a 4 to 8-membered heterocyclyl, wherein the 4 to 8-membered heterocyclyl contains one or more N, O or S(O)n, and the 4 to 8-membered heterocyclyl is optionally further substituted by one or more substituents selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, ═O, —C(O)R12, —C(O)OR12, —OC(O)R12, —NR13R14, —C(O)NR13R14, —S(O)nNR13R14 and —NR13C(O)R14;
R12, R13 and R14 are each independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more substituents selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxyl and carboxylate ester group; and
n is selected from 0, 1 and 2.

### Claim 2 (depends on 1)

The compound according to claim 1 or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, which is a compound of general formula (II) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof,
wherein R1 to R8 are as defined in claim 1.

### Claim 3 (depends on 1)

The compound or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof according to claim 1, which is a compound of general formula (III) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof,
wherein R1, R3 to R8 and Ra are as defined in claim 1.

### Claim 4 (depends on 1)

The compound or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof according to claim 1, which is a compound of general formula (IV) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof,
wherein R1, R3 to R8, Rb, Rc and n are as defined in claim 1.

### Claim 5 (depends on 3)

The compound or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof according to claim 3, which is a compound of general formula (V) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof,
wherein R1, R3 to R8 and Ra are as defined in claim 3.

### Claim 6 (depends on 4)

The compound or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof according to claim 4, which is a compound of general formula (VI) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof,
wherein R1, R3 to R8, Rb, Rc and n are as defined in claim 4.

### Claim 7 (depends on 1)

The compound or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof according to claim 1, wherein R3 is selected from
m is 0, 1, 2, 3 or 4; and
Rf is selected from C1-6 alkyl, C1-6 alkoxy, halogen and cyano, wherein C1-6 alkyl or C1-6 alkoxy is optionally further substituted by one or more halogens.

### Claim 8 (depends on 1)

The compound or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof according to claim 1, wherein R3 is selected from
m is 0, 1 or 2; and
Rf is selected from C1-6 alkyl, C1-6 alkoxy, halogen and cyano, wherein C1-6 alkyl or C1-6 alkoxy is optionally further substituted by one or more halogens.

### Claim 9 (depends on 7)

The compound or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof according to claim 7, wherein R3 is selected from
Rf is selected from fluorine, chlorine, cyano, methyl, methoxy, ethyl, isopropyl, difluoromethyl, trifluoromethyl and trifluoromethoxy.

### Claim 10 (depends on 1)

The compound or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof according to claim 1, wherein R8 is selected from
p is 0, 1, 2, 3 or 4; and
Rh is selected from C1-6 alkyl, C1-6 alkoxy, halogen and cyano, wherein C1-6 alkyl or C1-6 alkoxy is optionally further substituted by one or more halogens.

### Claim 11 (depends on 1)

The compound or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is selected from

### Claim at position 12

12-15. (canceled)

### Claim 16 (depends on 3)

A method of preparing the compound of general formula (III) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof according to claim 3, comprising
when Ra is an alkyl, reacting a compound of general formula (HID) with a compound of general formula (HIE), to obtain a compound of general formula (III) in which Ra is an alkyl;
optionally further performing a hydrolysis reaction of the compound of general formula (III) in which Ra is an alkyl to obtain a compound of general formula (III) in which Ra is hydrogen;
wherein:
X1 is a leaving group, preferably chlorine or hydroxy; and
R1 and R3 to R8 are as defined in claim 3.

### Claim 17 (depends on 5)

A method of preparing the compound of general formula (V) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof according to claim 5, comprising
when Ra is an alkyl, reacting a compound of general formula (VD) with a compound of general formula (HIE), to obtain a compound of general formula (V) in which Ra is an alkyl;
optionally further performing a hydrolysis reaction of the compound of general formula (V) in which Ra is an alkyl to obtain a compound of general formula (V) in which Ra is hydrogen;
wherein:
X1 is a leaving group, preferably chlorine or hydroxy; and
R1 and R3 to R8 are as defined in claim 5.

### Claim 18 (depends on 1)

A pharmaceutical composition comprising an effective amount of the compound, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof according to claim 1, and pharmaceutically acceptable carriers, excipients, or combinations thereof.

### Claim at position 16

19-22. (canceled)

### Claim 23 (depends on 1)

A method of treating or preventing diseases or disorders mediated by angiotensin II type 2 receptor, comprising administering to a patient in need thereof a therapeutically effective amount of the compound, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof according to claim 1, wherein the diseases or disorders mediated by angiotensin II type 2 receptor are preferably neuropathy or neuropathic pain, wherein the neuropathy or neuropathic pain is preferably primary neuropathy, secondary neuropathy, peripheral neuropathy, neuropathy caused by mechanical nerve injury or biochemical nerve injury, postherpetic neuralgia, diabetic neuralgia or related neurological diseases.
